Before settling on Heru, the company originally considered Horus as a potential name. The connection was clear—Horus, the Egyptian god of the sky and vision, directly aligned with the company’s mission in AI-driven ophthalmology. However, Horus presented multiple challenges that made it unviable as a long-term brand name.
The first issue was widespread use. Horus is a commonly referenced figure in mythology, business, and technology, making it difficult to own in a crowded branding and trademark landscape. Several companies across medical, AI, and tech industries had already registered trademarks or domain names under Horus, limiting its exclusivity and potential for differentiation.
Another challenge was cultural and industry positioning. While the symbolism of Horus made sense, it risked feeling too on-the-nose and potentially cliché for an advanced AI-driven medical technology company. A name that was more refined, unique, and ownable was needed to set Heru apart in a sophisticated way.
Shifting from Horus to Heru solved these issues while retaining the core symbolic power of vision and protection. Heru is the Egyptian name for Horus, keeping the connection intact while offering a shorter, more distinctive, and brandable alternative. It also ensured trademark availability and domain ownership, making it a more strategic and scalable choice.
Beyond the naming challenge, the company also had to establish differentiation in a highly technical, innovation-driven industry. The ophthalmology space is filled with clinical-sounding names and acronym-based brands, which often feel sterile or overly technical. Heru needed to stand out while maintaining credibility within both medical and AI communities.
Finally, the name needed to strike a balance between scientific authority and visionary ambition. Unlike traditional ophthalmology companies, Heru was introducing autonomous AI-driven diagnostics and augmentation, positioning itself at the forefront of medical technology, wearable devices, and artificial intelligence. The name had to capture both clinical credibility and cutting-edge innovation, ensuring it resonated with both medical professionals and tech-forward investors.